ITPA抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human fetal liver tissue, Hela cells, Primary antibody: P08911(ITPA Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P08911(ITPA Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08911(ITPA Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

**Background of ITPA Antibodies**

Inosine triphosphatase (ITPA) is an enzyme critical for maintaining nucleotide pool balance by hydrolyzing inosine triphosphate (ITP) to prevent its aberrant incorporation into RNA or DNA. ITPA deficiency, often linked to genetic polymorphisms (e.g., rs1127354), can lead to ITP accumulation, contributing to adverse drug reactions, particularly in patients treated with thiopurines (e.g., azathioprine). These drugs rely on proper nucleotide metabolism, and ITPA dysfunction may result in toxicity or therapeutic failure.

ITPA antibodies are tools used in research and diagnostics to detect ITPA protein levels or assess enzymatic activity, aiding in identifying genetic deficiencies or studying molecular mechanisms. While ITPA itself is not a common autoantigen in autoimmune disorders, antibodies against ITPA may be explored in niche contexts, such as rare immune-mediated conditions or drug-induced immune responses. Clinically, understanding ITPA status via antibody-based assays helps personalize thiopurine therapies, optimizing efficacy while minimizing toxicity. Ongoing research focuses on ITPA's broader roles in cellular stress responses, inflammation, and hematologic disorders, with antibodies serving as pivotal reagents in elucidating its pathophysiological relevance.

(Word count: 198)